2
Jun
2026

Ascendia Pharmaceutical Solutions

Exhibitor at CPHI Americas 2026 stand 1208
About Us

Ascendia Pharmaceutical Solutions is a specialty US CDMO providing custom formulation development and manufacturing. We deliver sophisticated formulations to enhance bioavailability, solubility and stability, while reducing toxicity using GRAS (Generally Regarded As Safe) materials and 4 proprietary nanotechnologies – NanoSol, EmulSol, AmorSol and LipidSol. Following formulation selection and optimization, Ascendia can scale-up a development program quickly to cGMP manufacturing of clinical materials. Ascendia offers both aseptic and non-aseptic manufacturing for small molecules and biologics.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    United States
  • Founded:
    2012
  • On CPHI since:
    2017
  • Certificates:
    2
  • Employees:
    50 - 99
Company types
CMO/CDMO
Manufacturer/Innovator
Primary activities
Contract Manufacturer
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Americas 2026
  • 2 Jun 2026 - 4 June 2026
  • Pennsylvania Convention Center, Philadelphia
  • Visit us at stand 1208

Products Featured at CPHI Americas 2026

  • AmorSol®

    Product AmorSol®

    Ascendia Pharmaceutical Solutions offers its AmorSol® platform: a technology for the production of amorphous solid dispersions. Solid dispersions are used to increase the dissolution rate, a limiting factor for the absorption of many compounds in development today. Contact us for more information.
  • cGMP clinical batches of injectable dosage forms

    Product cGMP clinical batches of injectable dosage forms

    Ascendia pharmaceuticals offers cGMP clinical batches of injectable dosage forms. Features: a dedicated, self-contained cleanroom for conducting sterile manufacturing and fill processes is maintained. Contact us for more information.
  • cGMP clinical batches of tablet and capsule dosage forms

    Product cGMP clinical batches of tablet and capsule dosage forms

    Ascendia pharmaceuticals offers cGMP clinical batches of tablet and capsule dosage forms. Features: it require capability to granulate, blend, and roller compact to make tablet batches for immediate release and modified release applications. Contact us for more information.
  • EmulSol®

    Product EmulSol®

    Ascendia Pharmaceutical Solutions offers its EmulSol® platform: a technology for production of oil-in-water nano-emulsions. Nano-emulsions are meta-stable and a high level of input energy is required to produce a nano-emulsion. Contact us for more information.
  • Lyophilization

    Product Lyophilization

    Ascendia pharmaceuticals offers lyophilization. Features: it is an equipment for producing pharmaceutical formulations. Contact us for more information.

Ascendia Pharmaceuticals Resources (1)

  • Drug Formulation Development Process Notes From A CDMO

    Whitepaper Drug Formulation Development Process Notes From A CDMO

    Pharma R&D productivity has remained stagnant in the new millennium, despite record industry growth. While new technology has improved productivity in nearly every other sector, efficiency in pharmaceutical R&D is declining (or as described by MedCity News — “broken”).What obstacles are in the way of improving productivity in the pharmaceutical industry? How can we meet these challenges? At Ascendia Pharma, we’re proud to have innovative strategies in place to help our clients get their drugs from R&D to market faster.